Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC’s 2nd Committee Recommends Approval for Astellas’ Prostate Cancer Treatment, Japan's First IPV
April 23, 2012
- MHLW Aims to Begin IPV Vaccination in September: Health Minister Komiyama
April 23, 2012
- MHLW Issues Improvement Order to Pfizer for GMP Violation at US BVL Plant
April 20, 2012
- PAL Amendment: Proposal Emerges to Submit Legislation by Diet Members for Third Party Organization
April 19, 2012
- Discussions on Use of Cost-Effectiveness Assessments to Begin with Advanced but Costly Technologies: MED Director Suzuki
April 19, 2012
- DPJ Working Team to Hold Hearings on Cost-Effectiveness Assessments, Pricing of Long-Listed Drugs on April 20
April 19, 2012
- Risk Management Plans to Be Required from April 2013 to Strengthen Post-Marketing Safety Measures
April 18, 2012
- PAFSC’s 1st Committee to Discuss Approval for MTPC’s DPP-4 Inhibitor Tenelia at Meeting on April 27
April 17, 2012
- Members of Non-Partisan Study Group Support Generic Drug Use Requirement for Welfare Recipients
April 16, 2012
- CSIMC Expert Subcommittee to Begin Discussion on Long-Listed Drugs in June, Also Deliberate on Targets for Generic Products
April 13, 2012
- CSIMC to Set Up New Subcommittee on Medicoeconomic Assessments
April 13, 2012
- CSIMC Approves Listing of Samtirel Without Restriction on Prescription Period
April 12, 2012
- CSIMC Approves 12 APIs/21 Products; Listing Scheduled for April 17
April 12, 2012
- Life Innovation Subcommittee to Recommence Activities, Including 5-Year Strategy: DPJ Project Team
April 12, 2012
- 16 Add’l Prefectures to Participate in Introductory GMP Training Course in Kinki Region
April 11, 2012
- Personnel Exchange Between PMDA, Universities to Facilitate Drafting of GL for Reviewing Innovative Drugs: Deputy Director Miyata of ELD
April 11, 2012
- PMDA to Establish Forum for Discussions Between Reviewers and Outside Researchers to Upgrade Its Ability to Review Cutting-Edge Drugs
April 10, 2012
- MHLW Issues Development Requests for 80 Drugs/Indications with Unmet Medical Needs
April 10, 2012
- MHLW Issues Safety Guidance for First-in-Human Trials
April 10, 2012
- PAFSC to Discuss Approval for Products Including Astellas’s Prostate Cancer Treatment Degarelix
April 9, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…